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Abstract: Epicardial Adipose Tissue (EAT) has been associated
with adverse cardiovascular events in the general population. We
studied the association of general adiposity measures (body mass
index, waist circumference) and ectopic adipose tissue [visceral
adipose tissue (VAT); liver fat (LF); EAT) with prevalent cardiovas-
cular disease (CVD) (prior myocardial infarction, coronary revascu-
larization, stroke, peripheral vascular disease] in 583 HIV-infected
men. VAT, EAT, and LF (liver/spleen attenuation ratio , 1.1) were
measured by computed tomography. Patients’ mean age was 48.5 ±
8.1 years, prior CVD was present in 33 (5.7%) patients. Factors in-
dependently associated with CVD on multivariable analyses were age
[incidence-rate ratio (IRR) = 1.07, 95% conﬁdence interval (CI): 1.02
to 1.12], smoking (IRR = 2.70, 95% CI: 1.22 to 6.01), Center for
Disease Control group C (IRR = 3.09, 95% CI: 1.41 to 6.76), EAT
(IRR = 1.13, 95% CI: 1.04 to 1.24, per 10 cm3), LF (IRR = 1.17, 95%
CI: 1.04 to 1.32), and VAT (IRR = 1.05, 95% CI: 1.00 to 1.10, per
10 cm3). Ectopic fat but not general adiposity measures were associ-
ated with prevalent CVD in men with HIV.
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INTRODUCTION
In the general population visceral adipose tissue (VAT)
has been demonstrated to correlate with traditional cardiovas-
cular risk factors: total cholesterol, low high-density lipoprotein
cholesterol, triglycerides, Apolipoprotein B, blood pressure,
insulin resistance, and C-reactive protein.1–3 It is believed that
VAT releases free fatty acids into the hepatic circulation, thus
stimulating the release of Apolipoprotein B–containing lipo-
proteins, reducing insulin sensitivity, and increasing plasma
glucose values.4,5 Furthermore, VAT releases several cytokines
that may be involved in the development of atherosclerosis.6
Epicardial adipose tissue (EAT) shares a common embryolog-
ical origin with VAT and is metabolically very active, secreting
proinﬂammatory cytokines at a higher rate than subcutaneous
and omental fat.7–9 It is postulated that EAT may inﬂuence
coronary atherosclerosis development via paracrine and sys-
temic effects; EAT has been associated with incident coronary
events in the general population10 and with VAT, fasting glu-
cose and insulin,11 and subclinical atherosclerosis12 in HIV. We
evaluated the association of adiposity measures [body mass
index (BMI)] and regional and ectopic fat [waist circumfer-
ence, VAT, EAT, and liver fat (LF)] with prevalent cardiovas-
cular disease (CVD) in 583 men with HIV infection.
METHODS
Subjects
Cross-sectional observational study of 583 consecutive
HIV-infected men receiving stable antiretroviral therapy
(ART) for at least 6 months referred to the Metabolic Clinic
of the University of Modena and Reggio Emilia, Italy,
between January 1, 2005, and December 31, 2009.
Assessments
Demographic characteristics, HIV infection history [Cen-
ter for Disease Control (CDC) classiﬁcation, type and duration
of ART (nucleoside reverse transcriptase inhibitor, nonnucleo-
side reverse transcriptase inhibitor, protease inhibitor)], smok-
ing, physical activity, blood pressure, weight, and height were
collected during patient encounters. Waist circumference was
averaged over 3 measurements and body mass index was
calculated as weight (kg)/height (m)2. Laboratory analyses in-
cluded the following: CD4+ count, plasma HIV-1 RNA, fasting
total cholesterol, LDL cholesterol, triglycerides, high-density
lipoprotein cholesterol, apolipoprotein A1 (Apo A), apolipopro-
tein B (Apo B), blood glucose, and insulin. The homeostasis
model assessment of insulin resistance (HOMA-IR) index was
calculated using the algorithm HOMA-IR = [(glucose, mmo/L ·
0.05551) · (insulin, mU/L)]/22.5 g. Lipodystrophy was diag-
nosed according to established criteria.13 A 10-year risk of CVD
was calculated with the modiﬁed Framingham equation.14
Prior cardiovascular events were deﬁned as myocardial
infarction (MI), coronary revascularization, stroke, peripheral
vascular disease that occurred within a 5-year period of the
computed tomography (CT) assessment of ectopic fat. Cardio-
vascular events reported by the patients or obtained from the
Metabolic Clinic charts were veriﬁed using the same classiﬁca-
tion criteria used for the D:A:D cohort; indeed, a subset of the
Metabolic Clinic patients is enrolled in the D.A.D. In particular,
Received for publication November 2, 2011; accepted January 17, 2012.
From the *Department of Medicine and Medical Specialties, University of
Modena and Reggio Emilia, Modena, Italy; †Department of Imaging, Uni-
versity of Modena and Reggio Emilia, Modena, Italy; and ‡Department of
Medicine, Division of Cardiology, Emory University, Atlanta, GA.
The authors have no funding or conﬂicts of interest to disclose.
Correspondence to: Guaraldi Giovanni, MD, Dipartimento di Mdedicine e
Specialità Mediche, Università di Modena e Reggio Emilia, Via del Pozzo
71, 41100 Modena, Italy (e-mail: giovanni.guaraldi@unimore.it).
Copyright © 2012 by Lippincott Williams & Wilkins
494 | www.jaids.com J Acquir Immune Defic Syndr  Volume 59, Number 5, April 15, 2012
MI’s are classiﬁed according to criteria applied in the World
Health Organization Monitoring Trends and Determinants in
Cardio-vascular Disease study.15
CT scans and measurements of VAT, EAT, and LF were
performed with a 64-multislice CT and associated workstation
(LightSpeed VTC; GE, Milwaukee, WI). VAT was measured
on a single abdominal CT section at the level of fourth lumbar
vertebra, and EAT was measured from the mid left atrium to
the left ventricular apex interpolating 10-mm thick slices with
an attenuation of −190 to −30 Hounsﬁeld Units, as described
before.16 The liver and spleen attenuation (in Hounsﬁeld Unit)
were measured in several circular areas of interest, and the
presence of LF was deﬁned as a liver-to-spleen ratio ,1.1.
Statistics
Variables are expressed as mean and SD or median and
interquartile range for continuous and percentage for categorical
variables. Univariate analyses (U Mann–Whitney for continu-
ous variables and Pearson x2 or Fisher exact text for categorical
variables) were conducted to explore factors associated with
CVD. Backward stepwise multivariable multilevel Poisson re-
gression analyses were conducted to identify factors indepen-
dently associated with CVD; we included age, BMI, waist
circumference, EAT, VAT, LF, current CD4 count, triglycer-
ides, total cholesterol, apolipoprotein A/apolipoprotein B ratio,
smoking, hypertension, diabetes mellitus, and cumulative ex-
posure to ART classes (nucleoside reverse transcriptase inhib-
itor, nonnucleoside reverse transcriptase inhibitor, and protease
inhibitor cumulative exposure). Incidence-rate ratios (IRR),
95% conﬁdence interval (CI), and P values were reported.
The strength of association between different measures
of ectopic fat, namely VAT, EAT, and LF (as a continuous
variable), was compared using receiver-operating character-
istic curves. The signiﬁcance of the difference of the area
TABLE 1. Clinical and Demographic Characteristics of the Sample
Variables
CVD Yes (33, 5.7%) Median (IQR)
or Mean (SD)
CVD No (550, 94.3%) Median (IQR)
or Mean (SD) P
Age, yrs 53 (47–62) 47 (44–52) ,0.0001
HIV duration, mo 194.5 (157.5–249) 181 (130–235.5) 0.091
CDC group C, n (%) 15 (45.4) 141 (25.6) 0.012
CD4 nadir, cells/mL 190 (50–241) 160 (60–274) 0.836
Past IVD use, n (%) 9 (27.3) 142 (25.8) 0.853
No physical activity, n (%) 22 (66.7) 293 (54.3) 0.154
Smoking, n (%) 16 (48.5) 48 (8.7) 0.179
HCV seropositive, n (%) 6 (18.2) 202 (37.2) 0.194
Alcohol consumption, n (%) 16 (48.5) 221 (40.7) 0.378
Waist circumference, cm 93.0 (7.7) 88.7 (9.8) 0.004
BMI 25.7 (3.0) 24.2 (3.6) 0.024
VAT, cm3 207.2 (85.7) 145.0 (72.7) ,0.0001
EAT, cm3 106 (81–169) 81 (56–103) ,0.0001
Liver fat diagnosis, n (%) 13 (5.3) 233 (94.7) 0.428
CD4 absolute count, cells/mL 524 (448–664) 523 (377–701) 0.805
HIV viral load undetectable, n (%) 18 (54.5) 305 (55.5) 1
NRTIs exposure, months 116 (76–157) 109 (49–146) 0.435
NNRTIs exposure, months 14 (0–45) 22 (0–54) 0.326
PIs exposure, months 59 (33–94) 39 (11–77) 0.077
Statin use n (%) 22 (66.7) 53 (9.7) ,0.001
No lipodystrophy, n (%) 0 77 (17) 0.024
Lipoatrophy, n (%) 5 (20) 187 (41.3) 0.037
Central fat accumulation, n (%) 5 (20) 43 (9.5) 0.094
Mixed form, n (%) 15 (60) 146 (32.2) 0.004
Diastolic pressure, mmHg 78.2 (11.8) 78.6 (11.2) 0.724
Systolic pressure, mmHg 123.0 (15.4) 121.5 (15.6) 0.547
Framingham risk score, % 12 (10–16) 8 (4–12) ,0.0001
Metabolic syndrome, n (%) 7 (21.9) 113 (21.7) 1
Triglycerides, mg/dL 179 (143–224) 166 (118–247) 0.485
Total cholesterol, mg/dL 193.2 (44.6) 188.1 (45.1) 0.413
HDL cholesterol, mg/dL 39.4 (11.2) 42.1 (12.0) 0.293
LDL cholesterol, mg/dL 119.8 (32.8) 114.1 (34.7) 0.239
ApoB/ApoA 0.83 (0.65–1.02) 0.73 (0.61–0.88) 0.031
HOMA-IR 3.74 (2.46–8.21) 2.85 (1.73–4.81) 0.040
ApoB/ApoA, apolipoprotein A/apolipoprotein B ratio; HCV, hepatitis C virus; HDL, high-density lipoprotein; HOMA-IR, homeostatis model of assessment of insulin resistance;
IQR, interquartile range; IVD, intravenous drug; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
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under the receiver-operating characteristic curves was tested
using the roccomp command on Stata. Statistical signiﬁcance
was P , 0.05. Stata software package, version 10.1 for Mac
(Intercooled; StataCorp LP, College Station, TX) was used
for the analyses.
RESULTS
The clinical characteristics of the 583 men included in
the study (33 with prior CVD events) are shown in Table 1.
Prior CVD events were as follows: MI in 27 patients, primary
angioplasty in 3 patients, and stroke in 3 patients.
CVD events occurred with a mean of 12.7 months
(range: 1–30.2) before ectopic fat measurements. Patients with
previous CVD were older, had a signiﬁcantly greater waist
circumference and BMI, and a higher prevalence of mixed
form lipodystrophy but lower prevalence of lipoatrophy than
subjects without prior CVD. VAT and EAT were signiﬁcantly
larger in patients with prior CVD compared with those without
CVD (P , 0.0001 for both), though the prevalence of LF was
not different between groups. HOMA-IR and apolipoprotein
A/apolipoprotein B ratio, also were higher in patients with
prior CVD (P = 0.031 and P = 0.040, respectively).
Factors independently associated with CVD in multi-
variable analyses were age (IRR = 1.07, 95% CI: 1.02 to 1.12,
P = 0.004), smoking (IRR = 2.70, 95% CI: 1.22 to 6.01, P =
0.015), CDC group C (IRR = 3.09, 95% CI: 1.41 to 6.76, P =
0.005), EAT (IRR = 1.13, 95% CI: 1.04 to 1.24, P = 0.003,
per 10 cm3), LF (IRR = 1.17, 95% CI: 1.04 to 1.32, P =
0.008, per 0.1 increase), and VAT (IRR = 1.05, 95% CI:
1.00 to 1.10, P = 0.028, per 10 cm3).
As shown in Figure 1, EAT and VAT seemed to have
a closer association than LF with CVD, although there was no
statistical difference between the areas under the curve of these
variables (P = 0.325). EAT and VAT were associated with pre-
vious CVD with the same sensitivity and speciﬁcity (P = 0.578).
DISCUSSION
In this cross-sectional sample of men with HIV infection
on a stable ART regimen, age, smoking, CDC group C, EAT,
and VAT—as measures of ectopic adiposity—were indepen-
dently associated with prevalent CVD, whereas measures of
total (BMI) and regional (waist circumference) adiposity were
not. Although this is a retrospective study, it provides a glance
into factors that may help improve cardiovascular risk assess-
ment in HIV. Recently, the role of general (BMI) and regional
(waist circumference) adiposity measures as a marker of CVD
risk in the general population has been criticised.17 Measures of
ectopic fat, however, have emerged as new important markers
of risk.4–10 LF seemed to be less sensitive and speciﬁc to pre-
dict prior CVD than EAT and VAT. This may reﬂect that CT
assessment of LF is less accurate than CT assessment of VAT
and EAT assessing relative density of the liver compared with
the spleen rather that a direct volume measurement.
EAT is associated with cardio metabolic risk factors,16,18–20
and it releases several inﬂammatory cytokines that might
inﬂuence the process of atherosclerosis in the coronary
arteries.21,22 In a population study, EAT was associated with
incident cardiovascular events independent of BMI and other
risk factors.10
The impact of intrabdominal accumulation of adipose
tissue in patients with HIV infection as a marker of
cardiovascular risk has been studied in connection with the
lipodystrophy syndrome.23 Interest in EAT has only recently
emerged, and this measure of ectopic adiposity has been
associated with cardio metabolic risk factors11 and subclinical
atherosclerosis.12–24 Although prospective studies will be nec-
essary to conﬁrm our observations, our ﬁndings suggest an
association between EAT and CVD in HIV men similar to
what has been reported in the general population.10 Of
interest, the EAT volume we measured in patients with prior
CVD was similar to that of a North American cohort of HIV
patients reported by Lo et al,11 whereas that of subjects with-
out prior CVD was comparable with HIV-negative patients in
the same study. As discussed elsewhere, EAT can be mea-
sured on the same chest CT images obtained for screening of
subclinical atherosclerosis in HIV patients,24 without adding
time and radiation exposure to the study. EAT can be mea-
sured also by transthoracic echocardiography,25 although the
measurements are less reproducible than with chest CT or
magnetic resonance.
Our study has several limitations, due to its retrospec-
tive nature and the measurement of EAT after the occurrence
of CVD events; furthermore, this study included only men
infected with HIV, and we cannot exclude a selection bias of
patient referred to the metabolic clinic. Therefore, caution
should be taken to attribute to EAT and/or VAT a causative
role in the genesis of CVD in HIV patients before prospective
studies are completed. Thus researchers should continue to
investigate the role of ectopic fat measurements that may
ultimately allow physicians to better discriminate patients at
increased risk of events and in need of more intense risk-
reduction programs.
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